Larazotide Peptide for Intestinal Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Intestinal barrier dysfunction leads to increased permeability, causing diseases such as enterocolitis, ischemic colitis, sepsis, and liver diseases like NAFLD and NASH, as the intestinal epithelium fails to prevent pathogens and toxins from entering the body.
Innovation Solution
Administering an effective amount of larazotide or its derivative to repair damaged intestinal epithelium, reduce leakiness, and improve barrier function, using sustained or controlled release formulations to avoid competitive inhibitors, and potentially combining with adjunct therapies like antibiotics or probiotics for synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If larazotide is administered to improve intestinal barrier function, then tight junction integrity is enhanced, but inactive fragments accumulate and act as competitive inhibitors
Solution Approach 1:
The patent extracts and removes the harmful inactive fragments (GVLVQPG and VLVQPG) from the larazotide molecule through targeted enzymatic cleavage. By using specific proteases to cleave the peptide bonds at known positions, the invention separates the active therapeutic component from the inhibitory fragments, allowing the active peptide to function without being counteracted by its own degradation products.
Solution Approach 2:
The invention changes the chemical parameters of larazotide by modifying the peptide sequence to include specific cleavage sites. This parameter change allows controlled degradation at predetermined positions, transforming the uncontrolled production of harmful fragments into a controlled process that generates removable byproducts while preserving the active therapeutic molecule.
2Reliability
If conventional dosing is used to treat intestinal permeability, then some therapeutic effect is achieved, but treatment frequency must be increased to maintain efficacy
Solution Approach 1:
The patent implements periodic action through sustained-release formulations that deliver larazotide at controlled intervals. Instead of requiring frequent dosing to maintain therapeutic levels, the formulation releases the active peptide periodically over an extended period, maintaining effective concentrations at the target site while reducing the burden of frequent administration.
Solution Approach 2:
The invention achieves continuity of useful action through controlled-release delivery systems that maintain steady-state concentrations of larazotide in the gastrointestinal tract. This continuous presence of the active molecule ensures uninterrupted therapeutic effect on tight junction integrity, eliminating the gaps in protection that occur with intermittent dosing.
Data Source
AI summary
The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.